1. Scrip
  2. >>Business
  3. >>Earnings

Tirzepatide Rules The Day On Lilly Earnings Call

Robust Sales In Diabetes And Obesity, Plus Good Data In NASH

 
• By Joseph Haas

Lilly reports better than 50% sequential sales growth for Mounjaro, while Zepbound’s early launch has brought in $176m. The company also unveiled positive Phase IIb data with tirzepatide in NASH.

Lilly office building
Lilly reports soaring sales for Mounjaro and Zepbound • Source: Shutterstock

Tirzepatide was virtually the exclusive focus of Eli Lilly and Company’s Q4 and full-year 2024 earnings call on 6 February as the company revealed significant growth for Mounjaro in type 2 diabetes, a strong launch for Zepbound in obesity and positive data from a Phase IIb study of tirzepatide in non-alcoholic steatohepatitis (NASH).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Ferring’s Faith In Bladder Cancer Gene Therapy Starts To Pay Off

 
• By Kevin Grogan

Adstiladrin sales hit €70m in first full year on the market

Regulatory And Macroeconomic Uncertainty Hang Over Q1 Earnings Season

 
• By Jessica Merrill

As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.

US Pharma Tariff Reprieve Appears Short-Lived

 
• By Jessica Merrill

Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.

Pharma Exhales, Dodging A Financial Blow With Tariff Exemption

 
• By Jessica Merrill

Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: Trump’s tariff rollercoaster; regulatory, economic uncertainties hang over Q1 earnings; IPOs rise in Q1 but may slow; Chinese deal-making matures; and AstraZeneca talks about Chinese innovation.

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

Biotech Leaders Ponder Tariff Ramifications

 
• By Joseph Haas, Mary Jo Laffler, and Jessica Merrill

Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.